Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

BACKGROUND: Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for “repurposing” as anti-viral agents. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Ananthula, Hari Krishna, Parker, Scott, Touchette, Erin, Buller, R. Mark, Patel, Gopi, Kalman, Daniel, Salzer, Johanna S., Gallardo-Romero, Nadia, Olson, Victoria, Damon, Inger K., Moir-Savitz, Tessa, Sallans, Larry, Werner, Milton H., Sherwin, Catherine M., Desai, Pankaj B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278073/
https://www.ncbi.nlm.nih.gov/pubmed/30514402
http://dx.doi.org/10.1186/s40360-018-0270-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278073/
https://www.ncbi.nlm.nih.gov/pubmed/30514402
http://dx.doi.org/10.1186/s40360-018-0270-x

Ejemplares similares